Skip to main content
Category

News

GREED WATCH: AbbVie Announces $13.87 Billion in Revenue

AbbVie announced during their earnings report today that it raked in $13.87 billion in revenue this quarter. While they make billions, Americans pay exorbitantly high prices for prescription drugs. AbbVie opposed the Biden administration reforms that lower prescription drug prices. 

  • During the call, AbbVie President & COO Rob Michael said he expects the company to meet its growth targets as the Inflation Reduction Act goes into effect: “… we feel good even with IRA although it does have an impact — has impacted everyone in the industry, we can still deliver on our long-term growth expectations.”
  • Drug companies charge Americans prices up to four times higher than prices in other countries, forcing patients to cut pills and skip doses to make ends meet. 
  • Over 80 percent of voters support giving Medicare the power to negotiate, making it the most popular provision in the Inflation Reduction Act. 

The Inflation Reduction Act brings down prescription drug costs for everyday Americans, especially seniors, by capping the price of insulin, giving Medicare the power to negotiate lower drug prices, and limiting the amount people have to pay each year for prescription drugs.  

Read more about why Medicare needs the power to negotiate lower drug costs and the five drugs that tell the story, including AbbVie’s Imbruvica, here.

GREED WATCH: Bristol-Myers Squibb Announces $11.2 Billion in Revenue and $4 Billion in Stock Buybacks

Bristol-Myers Squibb announced during their earnings report today that it raked in $11.2 billion this quarter. While they make billions, Americans pay exorbitantly high prices for prescription drugs. Bristol-Myers Squibb opposed the Biden administration reforms that lower prescription drug prices. 

  • During the call, CEO Giovanni Caforio bragged that “given our confidence in our future, this morning we also announced our intention to execute a $4 billion accelerated share repurchase in the third quarter.” 
  • Bristol-Myers Squibb announced it is rewarding its shareholders with $4 billion in stock buybacks over the next quarter. 
  • Bristol-Myers Squibb is suing the Biden administration to stop Medicare from negotiating lower drug prices for patients because it would endanger their massive profits. 
  • Drug companies charge Americans prices up to four times higher than prices in other countries, forcing patients to cut pills and skip doses to make ends meet. 
  • Over 80 percent of voters support giving Medicare the power to negotiate, making it the most popular provision in the Inflation Reduction Act. 

The Inflation Reduction Act brings down prescription drug costs for everyday Americans, especially seniors, by capping the price of insulin, giving Medicare the power to negotiate lower drug prices, and limiting the amount people have to pay each year for prescription drugs.  

Read more about why Medicare needs the power to negotiate lower drug costs and the five drugs that tell the story. 

GREED WATCH: GSK Announces Stronger Than Expected Profits Increase

GSK announced it raked in $8.98 billion this quarter in sales and is on track for higher than expected operating profit growth of 11 to 13 percent. While they make billions, Americans pay exorbitantly high prices for prescription drugs. GSK opposed the Biden administration reforms that lower prescription drug prices. 

  • During the call, CEO Emma Walmsley bragged about the company’s rapid revenue growth saying “For 2023, we now expect to deliver sales growth of 8% to 10% and adjusted operating profit growth of 11% to 13%”
  • GSK’s drug Trelegy has seen its sales increase by over 30 percent this quarter, almost single handedly growing their General Medicines portfolio by 10 percent. Trelegy is among the top drugs with the highest Medicare spending, and is likely to be selected for negotiation in the coming years. GSK charges Americans over $3,800 annually for Trelegy – over 2.5 times what Canadians have to pay – to have this life saving medicine. 
  • Drug companies charge Americans prices up to four times higher than prices in other countries, forcing patients to cut pills and skip doses to make ends meet. 
  • Over 80 percent of voters support giving Medicare the power to negotiate, making it the most popular provision in the Inflation Reduction Act. 

The Inflation Reduction Act brings down prescription drug costs for everyday Americans, especially seniors, by capping the price of insulin, giving Medicare the power to negotiate lower drug prices, and limiting the amount people have to pay each year for prescription drugs.  

Read more about why Medicare needs the power to negotiate lower drug costs and the five drugs that tell the story here

BREAKING: Democrats Unveil New Bill to Build on Inflation Reduction Act’s Provisions to Lower Drug Costs for the American People

Washington, DC — Today, House Democrats introduced a bill to build on the Inflation Reduction Act’s historic measures to lower prescription drug prices. The Lowering Drug Costs for American Families Act would increase the number of drugs subject to Medicare negotiation, extend inflation rebates to the private insurance market so drug prices don’t rise faster than inflation, and expand the savings from Medicare negotiation to Americans with private insurance, not just those covered by Medicare.

The new legislation comes as the Biden administration is working to implement the Inflation Reduction Act’s Medicare negotiation program. On September 1, the administration will release the first list of drugs for Medicare negotiations. While President Biden and Democrats in Congress are keeping up the fight to lower costs for American families, big drug companies and their Republicans allies are trying to move backwards by going to court and introducing legislation to stop Medicare from negotiating at all. The bill was introduced by Energy and Commerce Committee Ranking Member Frank Pallone, Jr. (D-NJ), Ways and Means Committee Ranking Member Richard E. Neal (D-MA), and Education and the Workforce Committee Ranking Member Robert C. “Bobby” Scott (D-VA).

In response, Protect Our Care Chair Leslie Dach issued the following statement: 

“Once again, Democrats are tackling the issues that matter most to Americans worried about the high cost of health care. Americans pay up to four times more for the same drugs as people in other countries, forcing people to cut pills in half or skip doses altogether. The Inflation Reduction Act has been a remarkable step forward to rein in Big Pharma’s greed, cap drug costs for seniors, and finally give Medicare the power to negotiate lower prices. More than 80 percent of Americans support the Inflation Reduction Act’s Medicare negotiation program, making it one of the most popular policies in recent history. It’s time to expand these savings to even more families no matter where they get their insurance.”

TODAY: U.S. Rep. Don Beyer, National Domestic Workers Alliance, Healthcare Storytellers to Join Protect Our Care Virginia to Discuss Biden Administration’s Efforts to Lower Rx Drug Costs Ahead of Upcoming Medicare Drug Negotiations

***MEDIA ADVISORY FOR WEDNESDAY JULY 26 at 9:30 AM EDT***

New Report Breaks Down Virginians’ Savings from Inflation Reduction Act 

Washington, D.C. — On Wednesday, July 26 at 9:30 AM U.S. Representative Don Beyer (D-VA-08) will join Protect Our Care Virginia to discuss the Biden-Harris administration’s next steps in implementing the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The administration released the final guidance outlining the process for negotiation, and by September 1, the ten drugs that are selected for the first round of price negotiations will be announced.

Speakers will also discuss a new fact sheet from Protect Our Care outlining how the Inflation Reduction Act reduces health care costs for Virginians— with even more savings on the way as the law’s provisions to give Medicare the power to negotiate and cap seniors’ prescription drug costs take effect. The new fact sheet follows new polling that shows the health care measures in the Inflation Reduction Act are the most popular in the entire bill.

This event comes as Republicans and big drug companies are attacking the Inflation Reduction Act in Congress and the courts. Pharmaceutical giants Merck, Bristol Myers Squibb, Astellas Pharma, and Johnson & Johnson-owned Janssen Pharmaceuticals, as well as the industry’s trade association PhRMA, are laser-focused on undermining the Inflation Reduction Act by filing lawsuits to protect their profits and stop the administration from negotiating lower drug prices. Big Pharma’s GOP allies in Congress have already introduced legislation to repeal the Inflation Reduction Act’s prescription drug provisions, which would increase drug costs for millions of seniors.

PRESS CALL:

WHO:
U.S. Representative Don Beyer (D-VA-08)
National Domestic Workers Alliance State Director Yanet Limon-Amado
Protect Our Care Virginia State Director Katie Baker
Medicare Storyteller Irv Varkonyi

WHAT: Virtual Press Conference

WHERE: Register to join the Zoom event (Registration required)

WHEN: Wednesday, July 26 at 9:30 AM EDT

###

BREAKING: New Report Shows Top Five Pharmaceutical Companies Raked in More Than $80 Billion In 2022

News Comes as Big Drug Companies Are in Court to Overturn Inflation Reduction Act’s Medicare Negotiation Program

Washington, DC — A new report from Accountable US shows that the five largest pharmaceutical companies (Eli Lilly, Johnson & Johnson, Merck, AbbVie, and Pfizer) raked in $81.9 billion in 2022 — an $8 billion increase from the previous year. In response, Protect Our Care Executive Director Brad Woodhouse issued the following statement:  

“Pharmaceutical greed knows no bounds. Right now, Americans are cutting pills and skipping doses because they can’t afford the prescription drugs that keep them alive. While drug companies continue to rake in record profits, they are crying wolf saying that any policy to make drugs more affordable for patients will harm innovation. Some of the top-earning drug companies are the same companies that are going to court to reverse the Inflation Reduction Act’s Medicare negotiation program, which would make prescription drugs more affordable for our nation’s seniors. It’s a complete disgrace that drug companies continue to put massive profits over a little bit of relief for seniors.”

TODAY: Representative Greg Stanton to Join Protect Our Care Arizona to Discuss Biden Administration’s Efforts to Lower Rx Drug Costs Ahead of Upcoming Medicare Drug Negotiations

***MEDIA ADVISORY FOR TUESDAY, JULY 25 at 10 AM MST // 1 PM EDT***

Thanks to the Inflation Reduction Act, Arizonans Are Saving on Health Care Costs

Phoenix, AZ – On Tuesday, July 25 at 10 AM MST // 1 PM EDT, U.S. Representative Greg Stanton (D-AZ-04) will join Protect Our Care Arizona, experts, and advocates to discuss the Biden-Harris administration’s next steps in implementing the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The administration released the final guidance outlining the process for negotiation, and by September 1, the ten drugs that are selected for the first round of price negotiations will be announced.

Speakers will also discuss a new fact sheet from Protect Our Care outlining how the Inflation Reduction Act reduces health care costs for Arizonans— with even more savings on the way as the law’s provisions to give Medicare the power to negotiate and cap seniors’ prescription drug costs take effect. The new fact sheet follows new polling that shows the health care measures in the Inflation Reduction Act are the most popular in the entire bill.

This event comes as big drug companies are attacking the Inflation Reduction Act in Congress and the courts. Pharmaceutical giants Merck, Bristol Myers Squibb, Astellas Pharma, and Johnson & Johnson-owned Janssen Pharmaceuticals, as well as the industry’s trade association PhRMA, are laser-focused on undermining the Inflation Reduction Act by filing lawsuits to protect their profits and stop the administration from negotiating lower drug prices. Big Pharma’s allies in Congress have already introduced legislation to repeal the Inflation Reduction Act’s prescription drug provisions, which would increase drug costs for millions of seniors.

PRESS CALL

WHO:
U.S. Representative Greg Stanton (D-AZ-04)
Will Humble, Executive Director, Arizona Public Health Association
Dora Vasquez, Executive Director, Arizona Alliance for Retired Americans
Kathy Saulsberry, Arizona Patient, and Health Care Advocate 

WHAT: Virtual Press Conference

WHEN: Tuesday, July 25 at 10 AM MST // 1 PM EDT

WHERE: Register to join the Zoom event (Registration required)

FACT SHEET: Republicans Continue To Promote Junk Plans That Have a History of Fraud & Are Dangerous For Patients

Republicans Promoting Junk Plans are Putting Big Insurance Company Profits Before Patients Once Again

This month, President Biden announced plans to rein in junk plans like short-term, limited-duration insurance (STLDI) plans that were previously expanded and promoted by the Trump administration. The fact of the matter is simple: junk plans engage in predatory marketing practices, fail to protect people with pre-existing conditions, and put patients at risk of bankruptcy when they get sick.

In 2018, the Trump administration changed the rules to allow these plans to be sold like regular insurance and gutted funding for advertising Affordable Care Act (ACA) marketplace plans — to disastrous effect. Far from promoting “consumer protection” and “consumer choice,” the Trump administration exposed consumers to scams and reduced transparency about coverage limits and hidden fees. These plans are particularly harmful for communities of color and other marginalized groups who are more likely to have poorer health and to be living in poverty. 

While some conservative voices claim that ending these rules could leave some uninsured, the Biden administration and Democrats in Congress have expanded access to no- or low-cost ACA coverage and funded outreach and enrollment so people are more likely to enroll in coverage that protects pre-existing conditions and less likely to get ripped off. Nearly 16.4 million people are enrolled in Marketplace coverage, including plans costing as little as $0 and $10/month. As the Biden administration works to lower health care costs and regulate these junk plans, Congressional Republicans are passing legislation to weaken protections for millions of people with pre-existing conditions and boost health insurance plans that aren’t required to cover prescription drugs or hospital care.

The Trump Administration Expanded Junk Plans and Gutted Funding For Advertising ACA Plans, Putting Consumers At Risk

The Trump Administration Cut Critical ACA Health Subsidies & Enabled Greater Access To Short-Term, Limited Duration Insurance (STLDI) Plans That Did Not Meet ACA Requirements. In late 2017, after Congressional Republicans’ efforts to repeal and replace the Affordable Care Act (ACA) failed to advance, then-President Trump ordered sweeping changes to health insurance with a pair of executive actions. He first announced that the sale of certain cheap policies with few benefits or protections – known as short-term, limited-duration insurance (STLDI) – would be allowed to be sold for up to 364 days with renewals for up to three years instead of three months, then announced cuts to critical health subsidies helping pay out-of-pocket costs for low-income people in America. In response, many patient and physicians groups raised concerns that junk plans would “cause significant economic harm to women and older, sicker Americans who stand to face higher-cost and fewer insurance options,” and “draw younger and healthier people away from the exchanges and drive additional plans out of the market.” The changes were solidified in August 2018 as a final rule allowing STLDI plans to be considered a form of individual health insurance coverage that would meet the ACA’s individual mandate.

Junk Plans Enabled By The Trump Administration Have Left Patients Without Protections For Pre-existing Conditions Afforded By the ACA. “Because they tend to look less expensive up front, short-term plans continue to find buyers, and they have been championed by the Trump administration (which has loosened restrictions on them) as an alternative for consumers. […] Consumer advocates have long sounded alarm bells about short-term plans and others that don’t comply with the Affordable Care Act rules — rules that require plans to provide comprehensive benefits to all comers, regardless of their health. The ACA also prohibits annual or lifetime dollar limits on coverage for any plan sold on the federal or state health insurance exchanges.” [NPR, 12/3/20]

Patient Advocacy Groups, Health Policy Experts, and Insurance Insiders Alike Have Warned Against Junk Plans’ Lack of Transparency and Coverage. Patient advocacy groups and health policy experts have long warned about the fraud risks that come with STLDI and other non-ACA-compliant plans. In January 2019, the Georgetown University Health Policy Institute found that consumers searching online for ACA-compliant plans were often directed, instead, to “junk plans.” Another study sponsored by the Leukemia and Lymphoma Society found that junk plans often rely on misleading marketing, are often misunderstood by consumers who purchase them with no right to appeal plan decisions, drive up patients’ out-of-pocket costs, and “threaten prices across the insurance market.” In March 2021, 30 patient organizations published a report pushing for greater regulation of dozens of different types of “junk insurance,” including STLDI plans. Even health insurance industry insiders have warned that the “very profitable” plans are inadequate, and state insurance regulators have expressed concerns that STLDI plan administrators have been misleading and taking advantage of consumers while offering substandard coverage.

Ever Since The Trump Administration’s Rule Change, Junk Plans Have Attracted Fraud. Following the Trump administration’s rule change, health insurance companies across the country began offering STLDI plans to consumers. Shortly after the rule took effect, federal officials shut down numerous “ruinous” health insurance plans that falsely claimed to provide comprehensive health insurance, with one commissioner describing them as a “classic bait-and-switch scheme designed to trick consumers.” 

  • 2022: A Florida-Based Health Insurance Company That Scammed Patients was Forced To Refund $100 Million After An FTC Investigation. One company, Health Insurance Innovations Inc. (later known as Benefytt Technologies), began using junk plans to scam consumers into paying exorbitant fees, often without their permission, for little coverage using deceptive websites such as “Obamacareplans.com.” In 2022, the Federal Trade Commission ordered the company to pay $100 million in refunds to customers who fell victim to the scam.

The Biden Administration Has Worked To Promote Informed Consumer Choice By Expanding Access To ACA Marketplace Plans And Launching Outreach Campaigns

The Biden Administration Has Expanded Critical Health Subsidies Allowing Millions of People To Access No- or Low-Cost ACA Plans. “Low-income Americans who missed signing up for 2022 Affordable Care Act coverage can now enroll in plans with $0 premiums through the federal exchange’s website. Those with incomes less than 150% of the federal poverty level – $19,320 for an individual and $39,750 for a family of four – can select policies on healthcare.gov through a special enrollment period, the Centers for Medicare and Medicaid Services told CNN exclusively on Monday. Most people will be able to select plans with no premiums, while others may have to pay a few dollars. 

The Biden Administration Has Promoted Informed Consumer Choice By Launching Advertising and Outreach Campaigns About Expanded ACA Access. “The agency is launching advertising and outreach campaigns to spread the word about the new special enrollment period, which lasts for the rest of the year. The effort will also target those experiencing certain life changes, such as losing job-based coverage, getting divorced or aging out of a parent’s policy, which have always allowed them to sign up for Obamacare policies during the year.” [CNN, 3/21/22]

While The Biden Administration Works To Lower Costs, Congressional Republicans Are Passing Legislation To Boost Junk Plans

The Biden Administration Is Working To Close Trump-Era Loopholes That Have Propped-Up Junk Plans. The Biden administration has worked to lower health care costs and crack down on “junk plans” like STLDI, proposing new rules closing Trump-era loopholes allowing health insurance companies to mislead patients and sell plans that provide very limited coverage. Under the new rules, STLDI plans will be limited to a maximum of 3 months – instead of 3 years as was allowed under the Trump administration – and will be required to disclose benefit limits as well as potential exposure to exorbitant surprise fees that disproportionately impact lower-income households and people of color.

…Meanwhile, Congressional Republicans Are Passing Legislation To Weaken Protections For Millions of People with Pre-Existing Conditions and Boost Health Insurance Plans That Fail To Cover Key Prescriptions & Hospital Care. In June 2023, Republicans held a markup on multiple pieces of legislation promoting “junk plans” that can discriminate against people with pre-existing conditions and fail to cover essential services like hospital visits and prescription drugs in order to undermine the ACA. One of these bills would expand access to association health plans (AHPs), a type of junk plan that leaves behind sick and at-risk individuals and undermines the ACA. Another would promote the use of non-ACA-compliant plans and other self-funded benefit plans. Further, these types of plans exploit communities of color and other marginalized communities, making Black, Latino, Asian, Indigenous, and LGBTQI+ people in America – who are more likely to be living in poverty than their White, heterosexual counterparts – more likely to face higher premiums.

GREED WATCH: Johnson & Johnson Announces $25.53 Billion in Revenue This Quarter, Record Growth for Shareholders

Johnson & Johnson announced it raked in $25.53 billion this quarter – $900 million over its expected revenue – during their earnings report today. While they make billions, Americans pay exorbitantly high prices for prescription drugs. Johnson & Johnson opposed the reforms that lower prescription drug prices, which were recently enacted by the Biden administration and Democrats in Congress. 

During the call, CEO Joaquin Duato bragged about the company’s “61st consecutive year of dividend increases” as well as stock buybacks totaling “$8.5 billion… in the first half of 2023.” Don’t forget: Johnson & Johnson is suing the federal government to stop Medicare from negotiating lower drug prices for patients because it would endanger their massive profits. Experts agree that this lawsuit is meritless as drug companies already negotiate with Medicaid and the VA. And nearly every other industry negotiates prices and discounts costs for large volumes – that’s how markets and competition work. 

Once again, we see that big drug companies like Johnson & Johnson are desperate to maintain the status quo that puts the greed of Wall Street above the needs of American families. Drug companies charge Americans prices up to four times higher than prices in other countries, forcing patients to cut pills and skip doses to make ends meet. Over 80 percent of voters support giving Medicare the power to negotiate, making it the most popular provision in the Inflation Reduction Act. 

The Inflation Reduction Act brings down prescription drug costs for everyday Americans, especially seniors, by capping the price of insulin, giving Medicare the power to negotiate lower drug prices, and limiting the amount people have to pay each year for prescription drugs.  

Read more about why Medicare needs the power to negotiate lower drug costs and the five drugs that tell the story, including Johnson & Johnson’s drug Xarelto, here

TODAY: U.S. Representative Scholten, Michigan State Representative Snyder, Health Care Advocates to Join Protect Our Care Michigan to Discuss Biden Administration’s Efforts to Lower Rx Drug Costs

***MEDIA ADVISORY FOR THURSDAY JULY 20 AT 1 PM EDT***

Thanks to the Inflation Reduction Act, Michiganders Are Saving on Health Care Costs

LANSING, MI – On Thursday, July 20 at 1 PM EDT, U.S. Representative Hillary Scholten, Michigan State Representative Will Snyder, and health care advocates will join Protect Our Care Michigan to discuss the Biden-Harris administration’s next steps in implementing the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The administration released the final guidance outlining the process for negotiation, and by Sept. 1, the 10 drugs that are selected for the first round of price negotiations will be announced. 

Speakers will also discuss a new fact sheet from Protect Our Care outlining how the Inflation Reduction Act reduces health care costs for Michiganders— with even more savings on the way as the law’s provisions to give Medicare the power to negotiate and cap seniors’ prescription drug costs take effect. The new fact sheet follows new polling that shows the health care measures in the Inflation Reduction Act are the most popular in the entire bill.

This event comes as Republicans and big drug companies are attacking the Inflation Reduction Act in Congress and the courts. Pharmaceutical giants Merck, Bristol Myers Squibb, Astellas Pharma, and Johnson & Johnson-owned Janssen Pharmaceuticals, as well as the industry’s trade association PhRMA, are laser-focused on undermining the Inflation Reduction Act by filing lawsuits to protect their profits and stop the administration from negotiating lower drug prices. Big Pharma’s GOP allies in Congress have already introduced legislation to repeal the Inflation Reduction Act’s prescription drug provisions, which would increase drug costs for millions of seniors.

PRESS CALL

WHO:
U.S. Representative Hillary Scholten (D-MI-03)
Michigan State Representative Will Snyder (D-87th District)
Rick Hainer, a senior citizen from Muskegon
Derrick Collins, Independent Living Team Manager, Grand Rapids-based Disability Advocates

WHAT: Virtual Press Conference

WHERE: Register to join the Zoom event (Registration required)

WHEN: Thursday, July 20, at 1 PM EDT